Patent number: 12630531
Abstract: A compound, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, provided as one aspect of the present invention, exhibits a high inhibitory ability on euchromatic histone-lysine N-methyltransferase 2 (EHMT2), and thus, the compound can be usefully used for the treatment of cancer.
Type:
Grant
Filed:
September 16, 2021
Date of Patent:
May 19, 2026
Assignee:
OMIC Smap Inc.
Inventors:
Jung Jin Hwang, Sang Eun Park, Dong Eun Kim, Ji-Ye Hong, Choung-Soo Kim, Woo Chan Son, Shinae Kim, Sugyeong Kwon, Kyungjin Jung, Nayeon Kim, Jina Kim, Kyung-Hee Kim, Jung Wook Chin, Sung Jin Cho, Sehan Lee, Eunju Cha, Jeongmin Joo, Ji Sun Hwang, Jeong-Eun Park, Ji Hoon Yu, Eunmi Hong, Young-Hoon Park, Ju-Hee Lee
Publication number: 20230365530
Abstract: A compound, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, provided as one aspect of the present invention, exhibits a high inhibitory ability on euchromatic histone-lysine N-methyltransferase 2 (EHMT2), and thus, the compound can be usefully used for the treatment of cancer.
Type:
Application
Filed:
September 16, 2021
Publication date:
November 16, 2023
Inventors:
Jung Jin HWANG, Sang Eun PARK, Dong Eun KIM, Ji-Ye HONG, Choung-Soo KIM, Woo Chan SON, Shinae KIM, Sugyeong KWON, Kyungjin JUNG, Nayeon KIM, Jina KIM, Kyung-Hee KIM, Jung Wook CHIN, Sung Jin CHO, Sehan LEE, Eunju CHA, Jeongmin JOO, Ji Sun HWANG, Jeong-Eun PARK, Ji Hoon YU, Eunmi HONG, Young-Hoon PARK, Ju-Hee LEE